Oracle Stocks Rise 2.4% as AstraZeneca Pact Opens an AI Healthca

Oracle (ORCL) shares rose 2.4% after announcing a nonbinding AI collaboration with AstraZeneca. The partnership explores clinical research and care workflows, but commercial terms and milestones are yet to be defined. Oracle aims to demonstrate how its technology can improve healthcare processes.

Amgen (AMGN) and AstraZeneca reported positive phase 3 trial results for Tezspire (tezepelumab) in treating eosinophilic esophagitis, showing significant remission and symptom improvement. Amgen has a 2.3% dividend yield, a 56% payout ratio, and a 7.1% 3-year dividend growth rate. The company's GF Score is 85/100, indicating strong financial health. Insiders have sold $29.3M in shares over the past year, while 12 gurus hold AMGN with slight net trimming.

Amgen and AstraZeneca reported phase 3 trial results for Tezspire in eosinophilic esophagitis, showing histologic remission in most patients and reduced swallowing difficulties. The CROSSING trial evaluated Tezspire 210 mg.

TD Cowen reports Nvidia NVDA may be supporting Oracle ORCL data centers through credit arrangements or leasing, citing recent leasing activity in Southeast Asia. Oracle is also exploring vendor financing for contracted capacity, according to the analyst. Neither company has commented on the claims.

Amgen (AMGN) and AstraZeneca (AZN) reported Phase III trial results for Tezspire in eosinophilic esophagitis, showing 68.9% of patients achieved histologic remission at 24 weeks, compared to 3.5% on placebo. The data, presented at UEG Week 2026, suggests potential for a new indication.

Amgen and AstraZeneca reported positive phase 3 trial results for Tezspire in treating eosinophilic esophagitis (EoE). The drug showed significant improvements in histologic remission and dysphagia symptoms. Amgen shares rose 2.4% and AstraZeneca shares increased 0.9%.